Precigen (STU:I5X) Moat Score: 4/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:I5X Precigen Inc STU:I5X
65 GF Score
Price €4.32
GF Value €5.13
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Precigen Moat Score?

Precigen STU:I5X 65 Moat Score is 4 as of Jul. 20, 2026. GuruFocus rates STU:I5X with a GF Score™ of 65/100 and a GF Value™ of €5.13 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 1,396 Biotechnology companies, Precigen ranks better than 88.83% on this metric.

Precigen has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Precigen has Narrow Moat: Precigen Inc has a discernible but modest moat due to its valuable intellectual property and patents in the biotechnology sector. However, the competitive landscape and regulatory challenges limit its ability to establish a stronger moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Precigen might have Narrow Moat - Discernible but modest moat.

Precigen  (STU:I5X) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Precigen Moat Score Related Terms

STU:I5X vs KARD, SLBT, GENB: Moat Score Comparison

For the Biotechnology subindustry, Precigen's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Precigen Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precigen's Moat Score distribution charts can be found below:

* The bar in red indicates where Precigen's Moat Score falls into.


STU:I5X
65GF Score
Precigen Inc STU:I5X
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Precigen (STU:I5X) has a Moat Score of 4 as of Jul. 20, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Precigen ranks #156 out of 1396 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Precigen's Moat Score too high?
Precigen's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Precigen's value of 4 is 100% above this industry median. Based on the distribution chart, Precigen ranks #156 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Precigen has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Precigen's Moat Score compare to KARD and SLBT?
According to the Biotechnology industry distribution chart, Precigen ranks #156 out of 1396 companies for Moat Score. This places Precigen in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Precigen's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precigen's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precigen's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.13, compared to a current price of €4.32 — trading 15.8% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Precigen's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Precigen (STU:I5X), the current Moat Score is 4 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precigen (STU:I5X) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of €4.32 is trading 15.8% below its estimated GF Value™ of €5.13. GuruFocus considers Precigen to be Modestly Undervalued.

Key valuation signals for STU:I5X:

  • Moat Score: 4
  • GF Value™: €5.13 vs. price of €4.32 (15.8% below fair value)
  • GF Score™: 65/100 with 8 warning signs
  • Industry Position: 100% above the Biotechnology median (#156 of 1396)

No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precigen Business Description

Other Exchanges PGEN:USA
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
65GF Score

Get the complete analysis for STU:I5X

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.32
Price
€5.13
GF Value